<DOC>
	<DOC>NCT00454701</DOC>
	<brief_summary>Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.</brief_summary>
	<brief_title>Assessment and Tracking of Long-term Alefacept Safety</brief_title>
	<detailed_description>There are no study-mandated tests, visits or clinical interventions after the 1st (enrolling) visit. After the patient is enrolled in the study, they will be contacted every 6 months to complete structured telephone interviews conducted by the ATLAS Study Center.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Psoriasis patients who are prescribed alefacept consistent with product labeling are eligible for enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Alefacept</keyword>
	<keyword>AmeviveÂ®</keyword>
	<keyword>Drug exposure</keyword>
</DOC>